Chronic Myelogenous Leukemia: Role of Stem Cell Transplant in the Imatinib Era

Nitin Jain; Koen Van Besien

doi:10.1016/j.hoc.2011.09.003

Chronic Myelogenous Leukemia: Role of Stem Cell Transplant in the Imatinib Era

Nitin Jain, Koen Van Besien

Research output: Contribution to journal › Review article › peer-review

11 Scopus citations

Abstract

In the pre-tyrosine kinase (TKI) era, allogeneic stem cell transplant (allo-SCT) was the front-line treatment of choice for young patients with chronic myelogenous leukemia (CML). Today, imatinib is well established as front-line therapy for CML, with excellent long-term outcomes. This has changed the role of allo-SCT and the number of patients undergoing allo-SCT has declined dramatically. Allo-SCT is currently recommended for patients in accelerated/blast phase disease, those who have failed a second-generation TKI and those with TKI-resistant mutations such as T315I. The role of allo-SCT in the management of CML will require continual reappraisal as medical therapies continue to evolve.

Original language	English (US)
Pages (from-to)	1025-1048
Number of pages	24
Journal	Hematology/Oncology Clinics of North America
Volume	25
Issue number	5
DOIs	https://doi.org/10.1016/j.hoc.2011.09.003
State	Published - Oct 2011
Externally published	Yes

Keywords

Allogeneic stem cell transplant
Chronic myelogenous leukemia
Imatinib
Tyrosine kinase inhibitors

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1016/j.hoc.2011.09.003

Cite this

@article{e104d4b1a177471b8f7d2b2b3253ed0a,

title = "Chronic Myelogenous Leukemia: Role of Stem Cell Transplant in the Imatinib Era",

abstract = "In the pre-tyrosine kinase (TKI) era, allogeneic stem cell transplant (allo-SCT) was the front-line treatment of choice for young patients with chronic myelogenous leukemia (CML). Today, imatinib is well established as front-line therapy for CML, with excellent long-term outcomes. This has changed the role of allo-SCT and the number of patients undergoing allo-SCT has declined dramatically. Allo-SCT is currently recommended for patients in accelerated/blast phase disease, those who have failed a second-generation TKI and those with TKI-resistant mutations such as T315I. The role of allo-SCT in the management of CML will require continual reappraisal as medical therapies continue to evolve.",

keywords = "Allogeneic stem cell transplant, Chronic myelogenous leukemia, Imatinib, Tyrosine kinase inhibitors",

author = "Nitin Jain and {Van Besien}, Koen",

year = "2011",

month = oct,

doi = "10.1016/j.hoc.2011.09.003",

language = "English (US)",

volume = "25",

pages = "1025--1048",

journal = "Hematology/Oncology Clinics of North America",

issn = "0889-8588",

publisher = "W.B. Saunders Ltd",

number = "5",

}

TY - JOUR

T1 - Chronic Myelogenous Leukemia

T2 - Role of Stem Cell Transplant in the Imatinib Era

AU - Jain, Nitin

AU - Van Besien, Koen

PY - 2011/10

Y1 - 2011/10

N2 - In the pre-tyrosine kinase (TKI) era, allogeneic stem cell transplant (allo-SCT) was the front-line treatment of choice for young patients with chronic myelogenous leukemia (CML). Today, imatinib is well established as front-line therapy for CML, with excellent long-term outcomes. This has changed the role of allo-SCT and the number of patients undergoing allo-SCT has declined dramatically. Allo-SCT is currently recommended for patients in accelerated/blast phase disease, those who have failed a second-generation TKI and those with TKI-resistant mutations such as T315I. The role of allo-SCT in the management of CML will require continual reappraisal as medical therapies continue to evolve.

AB - In the pre-tyrosine kinase (TKI) era, allogeneic stem cell transplant (allo-SCT) was the front-line treatment of choice for young patients with chronic myelogenous leukemia (CML). Today, imatinib is well established as front-line therapy for CML, with excellent long-term outcomes. This has changed the role of allo-SCT and the number of patients undergoing allo-SCT has declined dramatically. Allo-SCT is currently recommended for patients in accelerated/blast phase disease, those who have failed a second-generation TKI and those with TKI-resistant mutations such as T315I. The role of allo-SCT in the management of CML will require continual reappraisal as medical therapies continue to evolve.

KW - Allogeneic stem cell transplant

KW - Chronic myelogenous leukemia

KW - Imatinib

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=80755189388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80755189388&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2011.09.003

DO - 10.1016/j.hoc.2011.09.003

M3 - Review article

C2 - 22054733

AN - SCOPUS:80755189388

SN - 0889-8588

VL - 25

SP - 1025

EP - 1048

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

IS - 5

ER -

Chronic Myelogenous Leukemia: Role of Stem Cell Transplant in the Imatinib Era

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this